A Rationale for the Use of Clotted Vertebral Bone Marrow to Aid Tissue Regeneration Following Spinal Surgery

Area of Science:

• Orthopedics
• Regenerative Medicine
• Cell Biology

Background:

• Vertebral body bone marrow aspirate (V-BMA) is an emerging cell therapy in spinal surgery.
• Current V-BMA methods lack standardization and optimal structural integrity, risking cell diffusion.
• Mesenchymal stem cells (MSCs) are key components of V-BMA for therapeutic applications.

Purpose of the Study:

• To evaluate and compare the biological characteristics of MSCs derived from clotted, whole, and concentrated V-BMA.
• To identify the optimal V-BMA source for enhanced cell therapy in spinal procedures.
• To characterize MSCs' differentiation potential and gene expression profiles based on isolation method.

Main Methods:

• Isolation and culture of MSCs from clotted, whole, and concentrated V-BMA.
• Assessment of cell viability, growth factor expression (TGF-β, VEGF-A, FGF2), and colony-forming unit (CFU) potency.
• Analysis of osteogenic (COL1AI, TNFRSF11B, BGLAP), chondrogenic (SOX9), and adipogenic (ADIPOQ) differentiation potential.
• Evaluation of HOX and TALE gene signatures, including PBX1 and MEIS3 expression.

Main Results:

• MSCs from clotted V-BMA exhibited significantly higher cell viability and growth factor expression.
• Clotted V-BMA derived MSCs demonstrated superior CFU potency, cellular homogeneity, and osteogenic/chondrogenic differentiation.
• These MSCs showed a reduced capacity for adipogenic differentiation compared to other groups.
• Distinct HOX and TALE gene expression patterns were observed, with PBX1 and MEIS3 down-regulated in clotted V-BMA MSCs.

Conclusions:

• The cellular source within clotted V-BMA possesses the most favorable biological properties for spinal surgery.
• Clotted V-BMA represents a promising, advanced cell therapy alternative for patients undergoing spinal procedures.
• Standardizing V-BMA processing to utilize the clotted fraction could optimize cell therapy outcomes.